13A-1070315
US 11,582,957 B2
The invention demonstrates for the first time the feasibility of utilization of homologous single amino acid- knock-in strategy to dissect the critical effects on the initiation and propagation of ALS-TDP pathogenesis by specific ALS-associated TDP-43 mutations such as N390D and the associated mechanisms. The invention also shows that some ALS-associated mutations, such as A315T, would not necessarily lead to ALS pathogenesis, likely depending on the genetic background and environmental factors. The latter model(s) would be ideal for identification and/or validation of ALS-causing factors other than genetic ones. No similar mouse models have been reported before.
Currently, there is no effective drugs or therapeutic approaches that could be used for the preventative, treatment, or rescue of ALS. The ALS-TDP models with homologous, single amino acid- knock-in of ALS-associated mutations are ideal for the research and development of effective therapeutics, e.g. cell therapy, immunotherapy, and drugs treatments, for slowing down the ALS progression and even for preventive or rescue of this devastating disease.
The ALS-TDP models with homologous, single amino acid- knock-in of ALS-associated mutations are ideal for the research and development of effective therapeutics, e.g. cell therapy, immunotherapy, and drugs treatments, for slowing down the ALS progression and even for preventive or rescue of this devastating disease
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

ALS Pathogenesis of Knock-in Mouse Models with ALS-associated TDP-43 Mutations